Dietmar Neubacher

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Julio Rosenstock, Jan Marquard, Lori M. Laffel et al. · Diabetes Care · 2018 · 339 citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B. Hicks, Pedro Cahn, David A. Cooper et al. · The Lancet · 2006 · 322 citations

Durable Efficacy, Treatment-experienced Hiv-1-infected Patients, Hiv/aids Counselling +13

Effect of linagliptin monotherapy on glycaemic control and markers of <i>β</i> ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Stefano Del Prato, Anthony Barnett, Holger Huisman et al. · Diabetes Obesity and Metabolism · 2010 · 296 citations

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith et al. · The Lancet Diabetes & Endocrinology · 2023 · 98 citations · Full text

Metabolic Syndrome, Diabetes Management, Young People +11

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher et al. · Cardiovascular Diabetology · 2015 · 81 citations · Full text